Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
83 Results for "
HER2-positive
" in MedChemExpress (MCE) Product Catalog:
Products (83)
83 Results for "HER2-positive" in MCE Product Catalog:
66
66 Publications Verification
Cat. No.: HY-P9907
CAS No.: 180288-69-1
Synonyms: Anti-Human HER2, Humanized Antibody
Research Areas:
66
66 Publications Verification
Cat. No.: HY-P9907A
CAS No.: 180288-69-1
Synonyms: Anti-Human HER2, Humanized Antibody (anti-HER2)
Target:
Research Areas:
10
10 Cited Publications
Cat. No.: HY-P9912
CAS No.: 380610-27-5
10
10 Cited Publications
Cat. No.: HY-P9912A
CAS No.: 380610-27-5
9
9 Cited Publications
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
9
9 Cited Publications
Synonyms: T-DXd; DS-8201; DS-8201a
5
Target:
Research Areas:
Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate (ADC), formed by conjugation of the humanized anti-HER2 antibody Disitamab (HY-P99854) with drug-linker VcMMAE (HY-15575). VcMMAE consists of a cleavable MC-Val-Cit-PAB linker and the microtubule inhibitor MMAE (HY-15162). After binding to HER2 and undergoing endocytosis, Disitamab vedotin releases MMAE in lysosomes, which further inhibits microtubule assembly, arrests mitosis and induces apoptosis, while also exerting a bystander effect. Disitamab vedotin can be used in studies of HER2-positive breast cancer [2] .
4
4 Cited Publications
Target:
Research Areas:
ZCL278 is a selective Cdc42 inhibitor with Kds of 6.4 μM in fluorescence titration and 11.4 μM in surface plasmon resonance (SPR) measurement. ZCL278 is able to disrupt the Cdc42-ITSN interaction as well as GTP/GDP binding. ZCL278 has inhibitory effects on various enveloped viruses, but is ineffective against non-enveloped viruses. ZCL278 can be used for the studies of arsenic neurotoxicity and HER2-positive gastric cancer (GC) [2] .
3
2
2 Cited Publications
Cat. No.: HY-N1073
CAS No.: 51225-30-0
Synonyms: 6-Isopentenylgenistein; Erythrinin B
Category:
1
1
1 Cited Publications
CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12 .
Cat. No.: HY-164202
Target:
Research Areas:
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 exhibits robust efficacy across 14 HER2-positive breast cancer cell lines, with IC50 values ranging from 0.3 to 14.4 nM.ORM-5029 demonstrates anti-tumor activity in the BT474 xenograft model. ORM-5029 can be used for study of breast cancer [2] .
Research Areas:
PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader (MZ 1 (HY-107425) analog) and PEG-based linker. PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. PROTAC BRD4 Degrader-5-CO-PEG3-N3 can be used for the research of HER2-positive breast cancer .
Cat. No.: HY-P99618
CAS No.: 2377419-89-9
Synonyms: IBI-315; BH2950
Target:
Research Areas:
NCT-58 is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells .
Cat. No.: HY-P991149
CAS No.: 2966936-23-0
Synonyms: YH32367; ABL105
Target:
Research Areas:
Cat. No.: HY-P99030
CAS No.: 1350624-75-7
Synonyms: MGAH-22
Cat. No.: HY-164762
CAS No.: 2924909-11-3
Synonyms: SHR-A1811
Cat. No.: HY-P99866
CAS No.: 1314238-96-4
Synonyms: MEHD-7945A; RG 7597
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
